Clinical trials: Salivary Gland Cancer
Head and Neck Cancer, Psychosocial Effects of Cancer and Its Treatment
Measuring Patient Satisfaction With Facial Appearance: Development and Validation of a New Patient-Reported Outcome Measure
RATIONALE: Developing a questionnaire that patients can use to assess their quality of life related to the appearance of their face after surgery may help doctors plan the best treatment for patients undergoing surgery and…
- Trial name
- NCT00530049
- Testing
- questionnaire administration, assessment of therapy complications, psychosocial assessment and care
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 1,745 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Paranasal Sinus Neoplasms, Nasopharyngeal Carcinoma
- Trial name
- NCT07667400
- Testing
- SX-682, DTX
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Salivary Gland Tumor
Partial Modified Blair Incision on Benign Tumor Parotidectomy Scar's Characteristics
Parotidectomy is the treatment of choice for tumors in the parotid gland, with the modified Blair is the most common incision used.
- Trial name
- MiniBlair (NCT04970875)
- Testing
- Questionnaire
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- Western Galilee Hospital-Nahariya
Head and Neck Cancer
S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as E7389, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00337129
- Testing
- eribulin mesylate
- Where
- 139 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations
Evaluating the efficacy of Neratinib tablets monotherapy in treating advanced solid tumors with HER2 mutations.
- Trial name
- CVL009-C2001 (NCT06519110)
- Testing
- Neratinib tablets
- Volunteers
- 60 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Head and Neck Cancer
Nutritional Status and Barriers to Dietary Intake in Head and Neck Cancer Patients
The investigators hope to learn more about how side-effects of RT or RTchemo affect food intake and nutrition status.
- Trial name
- NCT00375180
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- AHS Cancer Control Alberta
Head Neck Cancer, Xerostomia Following Radiotherapy
Pretreatment Botulinum Toxin in Head and Neck Cancer Surgery
Head and neck cancer care, including tumors of the mouth, nose, throat and voice box, often requires radiation for cure to be achieved.
- Trial name
- NCT06530524
- Testing
- OnabotulinumtoxinA
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital
Oral Squamous Cell Carcinoma
Salivary LINC00657 as a Diagnostic Biomarker for Oral Squamous Cell Carcinoma
This study was designed to verify the role of salivary LINC00657 as a diagnostic marker in oral squamous cell carcinoma (OSCC) patients as compared to oral lichen planus (OLP) (as an example of oral potentially malignant lesions)…
- Trial name
- NCT05821179
- Where
- Egypt
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Fayoum University
SCAD, Addison Disease
Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity
This case control study aims to determine whether spontaneous coronary artery dissection (SCAD) is associated with autoimmune diseases and to update the incidence of SCAD in a population-based cohort.
- Conditions
- SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome
- Trial name
- NCT03941184
- Where
- United States
- Volunteers
- 114 people
- Sponsor
- Mayo Clinic
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
Phase I trial to study the effectiveness of erlotinib in treating patients who have metastatic or unresectable solid tumors and liver or kidney dysfunction.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Brain Stem Glioma
- Trial name
- NCT00030498
- Testing
- erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- National Cancer Institute (NCI)
Salivary Gland Dysfunction, Xerostomia
Everolimus in Restoring Salivary Gland Function in Participants With Locally Advanced Head and Neck Cancer Treated With Radiation Therapy
This early phase 1 trial studies the use of everolimus in restoring salivary gland function in participants with locally advanced head and neck cancer after concurrent chemoradiation or radiation therapy alone.
- Conditions
- Salivary Gland Dysfunction, Xerostomia, Head and Neck Cancer
- Trial name
- NCT03578432
- Testing
- Everolimus, Laboratory Biomarker Analysis, Survey Administration
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Arizona
Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
This is an open-label, multi-center, single arm, Phase II study to evaluate the efficacy and safety of T-DXd for the treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless…
- Trial name
- DPT01 (NCT04639219)
- Testing
- Trastuzumab deruxtecan
- Where
- 30 sites in United States, Belgium and 7 more
- Volunteers
- 102 people
- Sponsor
- AstraZeneca
Salivary Glands Tumors
Abiraterone Acetate in Patients With Relapsed and/or Metastatic Salivary Gland Cancers
Carcinomas of the salivary glands (SGCs) are rare tumors. Some selected salivary gland histotypes such as salivary duct carcinomas (SDC) and adenocarcinomas, NOS (not otherwise specified) distinguish themselves for the expression…
- Trial name
- SG-ABI14 (NCT02867852)
- Testing
- Abiraterone acetate
- Where
- Italy
- Volunteers
- 24 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Cancer
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00049296
- Testing
- docetaxel, thalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip
Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer
This phase I trial studies the side effects and best dose of photodynamic therapy using HPPH in treating patients who are undergoing surgery for primary or recurrent head and neck cancer.
- Conditions
- Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity, Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity
- Trial name
- NCT00470496
- Testing
- HPPH, photodynamic therapy, conventional surgery
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
This phase II trial compares the effect of usual treatment of docetaxel chemotherapy plus trastuzumab, to ado-emtansine (T-DM1) in patients with HER2-positive salivary gland cancer that has come back (recurrent), that has spread…
- Conditions
- Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8
- Trial name
- NCT05408845
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 154 sites in United States
- Volunteers
- 146 people
- Sponsor
- NRG Oncology
Parotid Neoplasms
Symptoms of Frey's Syndrome
The goal of this observational study is to describe the prevalence of typical and atypical signs and symptoms of Frey's syndrome, the affected areas and the severity of each symptom/sign.
- Trial name
- NCT05738395
- Testing
- Questions
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer
Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one chemotherapy drug may kill more tumor cells.
- Trial name
- NCT00010023
- Testing
- capecitabine, cisplatin
- Where
- United States
- Sponsor
- NYU Langone Health
Oropharynx Cancer, Head and Neck Cancer
Sparing Parotid Ducts Via MRI Sialography for Reduced Patient Reported Xerostomia
Radiation-induced xerostomia (dry mouth) is one of the most common and severe toxicities experienced by patients undergoing radiation treatment for head and neck cancer.
- Conditions
- Oropharynx Cancer, Head and Neck Cancer, Xerostomia
- Trial name
- NCT06276946
- Testing
- standard radiotherapy, experimental radiotherapy
- Where
- United States
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Head and Neck Cancer
Adjuvant Erlotinib After Completing Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Giving erlotinib after chemoradiotherapy may kill more tumor cells.
- Trial name
- NCT00079053
- Testing
- erlotinib hydrochloride, adjuvant therapy
- Where
- 2 sites in Canada
- Volunteers
- 19 people
- Sponsor
- NCIC Clinical Trials Group